Eleanor Barnes

List of Publications by Year
in descending order

256 papers	29,134 citations	14614 66 h-index	6979 154 g-index
301 all docs	301 docs citations	301 times ranked	38384 citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 2015, 61, 77-87.	3.6	1,293
4	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
5	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	7.0	1,066
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
7	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
8	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
9	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	13.5	630
10	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factorâ€“neutralizing therapy in patients with inflammatory bowel disease. Nature Medicine, 2017, 23, 579-589.	15.2	571
11	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	13.5	532
12	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
13	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
14	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	13.5	442
15	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology, 2021, 74, 567-577.	1.8	377
16	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
17	Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Journal of Hepatology, 2014, 60, 69-77.	1.8	367
18	Analysis of CD161 expression on human CD8⁺T cells defines a distinct functional subset with tissue-homing properties. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3006-3011.	3.3	359

#	Article	IF	Citations
19	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1.	5.8	356
20	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 2022, 7, 1161-1179.	5.9	352
21	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infectious Diseases, The, 2020, 20, 1390-1400.	4.6	336
22	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153.	5.8	297
23	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology, 2004, 127, 924-936.	0.6	276
24	COVID-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 348-364.	8.2	272
25	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
26	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262
27	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2.	5.8	257
28	Human MAIT and CD8Î±Î± cells develop from a pool of type-17 precommitted CD8+ T cells. Blood, 2012, 119, 422-433.	0.6	239
29	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology, 2015, 149, 1462-1470.	0.6	214
30	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary resultsÂfrom an international registry. Journal of Hepatology, 2020, 73, 705-708.	1.8	213
31	Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort. American Journal of Gastroenterology, 2014, 109, 1675-1683.	0.2	210
32	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. The Lancet Gastroenterology and Hepatology, 2020, 5, 1008-1016.	3.7	194
33	Genetic History of Hepatitis C Virus in East Asia. Journal of Virology, 2009, 83, 1071-1082.	1.5	190
34	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
35	Antibody testing for COVID-19: A report from theÂNational COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	0.9	179
36	Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. Journal of Hepatology, 2016, 64, 308-315.	1.8	170

#	Article	IF	Citations
37	Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. American Journal of Gastroenterology, 2016, 111, 733-743.	0.2	167
38	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
39	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology, 2019, 156, 418-430.	0.6	162
40	Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4â€associated cholangitis from primary sclerosing cholangitis. Hepatology, 2014, 59, 1954-1963.	3.6	158
41	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	1.8	158
42	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
43	Multiparametric magnetic resonance imaging for the assessment of nonâ€alcoholic fatty liver disease severity. Liver International, 2017, 37, 1065-1073.	1.9	145
44	The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology, 2002, 36, 743-754.	3.6	132
45	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	3.6	131
46	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe, The, 2022, 3, e21-e31.	3.4	131
47	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nature Genetics, 2017, 49, 666-673.	9.4	129
48	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	122
49	CD161intCD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunology, 2016, 9, 401-413.	2.7	121
50	Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1444-1452.e6.	2.4	116
51	Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. Journal of Clinical Microbiology, 2016, 54, 2470-2484.	1.8	112
52	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
53	Vaccination for hepatitis C virus: closing in on an evasive target. Expert Review of Vaccines, 2011, 10, 659-672.	2.0	103
54	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102

#	Article	IF	Citations
55	Interferon lambdas: the next cytokine storm. Gut, 2011, 60, 1284-1293.	6.1	100
56	Pervasive Influence of Hepatitis C Virus on the Phenotype of Antiviral CD8+ T Cells. Journal of Immunology, 2004, 172, 1744-1753.	0.4	98
57	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. Frontiers in Immunology, 2018, 9, 486.	2.2	91
58	Determining risk factors for mortality in liver transplant patients with COVID-19. The Lancet Gastroenterology and Hepatology, 2020, 5, 643-644.	3.7	90
59	SARS-CoV-2 infection in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 74, 1335-1343.	1.8	90
60	MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science, 2021, 371, 521-526.	6.0	88
61	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 2020, 5, 181.	0.9	81
62	Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines. Cell Reports, 2018, 23, 768-782.	2.9	79
63	Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 1406-1407.	1.1	77
64	Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state. Nucleic Acids Research, 2017, 45, e148-e148.	6.5	77
65	Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV). Scientific Reports, 2019, 9, 7081.	1.6	75
66	Prevention of infection caused by immunosuppressive drugs in gastroenterology. Therapeutic Advances in Chronic Disease, 2013, 4, 167-185.	1.1	72
67	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunology, 2018, 11, 562-574.	2.7	71
68	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology, 2019, 69, 1861-1872.	3.6	68
69	ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Research, 2015, 4, 1062.	0.8	66
70	Hepatic iron is the major determinant of serum ferritin in <scp>NAFLD</scp> patients. Liver International, 2018, 38, 164-173.	1.9	65
71	A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples. PLoS ONE, 2013, 8, e66129.	1.1	62
72	Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1855-1860.	3.3	61

#	Article	IF	Citations
73	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	3.6	60
74	Impact of Alpha Interferon and Ribavirin on the Function of Maturing Dendritic Cells. Antimicrobial Agents and Chemotherapy, 2004, 48, 3382-3389.	1.4	57
75	Ultra-sensitive classâ€„I tetramer analysis reveals previously undetectable populations of antiviral CD8+ Tâ€„cells. European Journal of Immunology, 2004, 34, 1570-1577.	1.6	57
76	Estimating the net contribution of interleukinâ€28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011, 53, 1446-1454.	3.6	56
77	Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. ELife, 2020, 9, .	2.8	55
78	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	5.8	54
79	Ever closer to a prophylactic vaccine for HCV. Expert Opinion on Biological Therapy, 2013, 13, 1109-1124.	1.4	53
80	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology, 2020, 159, 1276-1289.e7.	0.6	53
81	Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. Immunology Letters, 2003, 85, 165-171.	1.1	51
82	Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity â€“ The OCTAVE Trial. SSRN Electronic Journal, 0, , .	0.4	51
83	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet, The, 2005, 365, 327-329.	6.3	50
84	A Theoretical Framework for Quantitative Analysis of the Molecular Basis of Costimulation. Journal of Immunology, 2005, 175, 1575-1585.	0.4	49
85	Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores. American Journal of Clinical Pathology, 2017, 147, 364-369.	0.4	49
86	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. The Lancet Gastroenterology and Hepatology, 2021, 6, 156-158.	3.7	49
87	Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology, 2010, 51, 54-62.	3.6	48
88	Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. Journal of Allergy and Clinical Immunology, 2014, 133, 267-270.e6.	1.5	48
89	Applications and Limitations of Blood Eosinophilia for the Diagnosis of Acute Cellular Rejection in Liver Transplantation. American Journal of Transplantation, 2003, 3, 432-438.	2.6	47
90	Cellular Immune Responses during Highâ€Dose Interferonâ€Ì± Induction Therapy for Hepatitis C Virus Infection. Journal of Infectious Diseases, 2009, 199, 819-828.	1.9	47

#	Article	IF	Citations
91	Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR. Emerging Infectious Diseases, 2016, 22, 671-678.	2.0	46
92	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Medicine, 2013, 14, 1-71.	1.0	43
93	Chronic hepatitis C viral infection subverts vaccineâ€induced Tâ€cell immunity in humans. Hepatology, 2016, 63, 1455-1470.	3.6	43
94	Characterization of the Specificity, Functionality, and Durability of Host Tâ€Cell Responses Against the Fullâ€Length Hepatitis E Virus. Hepatology, 2016, 64, 1934-1950.	3.6	42
95	Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2021, 28, 493-507.	1.0	42
96	Cell-free DNA TAPS provides multimodal information for early cancer detection. Science Advances, 2021, 7, eabh0534.	4.7	41
97	Failure to Detect Xenotropic Murine Leukemia Virusâ€“Related Virus in Blood of Individuals at High Risk of Bloodâ€Borne Viral Infections. Journal of Infectious Diseases, 2010, 202, 1482-1485.	1.9	40
98	Discovery of Novel Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients: A Preliminary Study. PLoS ONE, 2012, 7, e39603.	1.1	40
99	The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 475-483.	0.7	39
100	Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of antiâ€MicroRNAâ€122, RGâ€101. Hepatology, 2017, 66, 57-68.	3.6	39
101	A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. Journal of Clinical Microbiology, 2020, 58, .	1.8	39
102	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	2.1	39
103	Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease. Annals of the Rheumatic Diseases, 2015, 74, 944-947.	0.5	37
104	Prognostic value of multiparametric magnetic resonance imaging, transient elastography and bloodâ€based fibrosis markers in patients with chronic liver disease. Liver International, 2020, 40, 3071-3082.	1.9	37
105	Therapeutic vaccination for treatment of chronic hepatitis B. Clinical and Experimental Immunology, 2021, 205, 106-118.	1.1	36
106	SARSâ€CoVâ€2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVIDâ€19 Vaccination. Hepatology Communications, 2022, 6, 889-897.	2.0	36
107	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines, 2016, 4, 27.	2.1	35
108	Crossâ€reactivity of hepatitis C virus specific vaccineâ€induced T cells at immunodominant epitopes. European Journal of Immunology, 2015, 45, 309-316.	1.6	34

#	Article	IF	Citations
109	The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine, 2018, 36, 313-321.	1.7	32
110	Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. Journal of Viral Hepatitis, 2008, 15, 219-228.	1.0	31
111	HCV genotypesâ€"role in pathogenesis of disease and response to therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 229-240.	1.0	30
112	Immunity to hepatitis C virus: stunned but not defeated. Microbes and Infection, 2002, 4, 57-65.	1.0	30
113	The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut, 2016, 65, 112-123.	6.1	30
114	Unique patterns of glycosylation in immunoglobulin subclass G4â€related disease and primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1878-1886.	1.4	30
115	The Application of Single-Cell RNA Sequencing in Vaccinology. Journal of Immunology Research, 2020, 2020, 1-19.	0.9	30
116	Thoracic involvement in IgG4-related disease in a UK-based patient cohort. Respiratory Medicine, 2017, 132, 117-121.	1.3	29
117	Interpreting Viral Deep Sequencing Data with GLUE. Viruses, 2019, 11, 323.	1.5	29
118	Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. Clinical and Translational Gastroenterology, 2019, 10, e00020.	1.3	29
119	Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney andÂRetroperitoneal Involvement inÂaÂUnited Kingdom IgG4-Related Disease Cohort. Kidney International Reports, 2019, 4, 48-58.	0.4	29
120	Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing. Journal of Clinical Microbiology, 2015, 53, 3155-3164.	1.8	28
121	Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. Journal of General Virology, 2010, 91, 1396-1406.	1.3	28
122	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. ELife, 2019, 8, .	2.8	28
123	Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection. Journal of Virology, 2009, 83, 11456-11466.	1.5	27
124	An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes. Virology, 2015, 476, 355-363.	1.1	27
125	No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort. Pancreatology, 2017, 17, 395-402.	0.5	27
126	Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. PLoS ONE, 2019, 14, e0221066.	1.1	27

#	Article	IF	Citations
127	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology, 2019, 157, 692-704.e9.	0.6	27
128	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Frontiers in Immunology, 2018, 9, 3175.	2.2	27
129	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology, 2020, 73, 794-799.	1.8	27
130	CD8Î±Î± Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection. Frontiers in Immunology, 2013, 4, 223.	2.2	26
131	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
132	CD161+CD4+ T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-Î³. Frontiers in Immunology, 2012, 3, 346.	2.2	25
133	Treatment of chronic viral hepatitis C in children and adolescents: UK experience. Archives of Disease in Childhood, 2014, 99, 505-510.	1.0	25
134	Phosphodiester content measured in human liver by in vivo ³¹P MR spectroscopy at 7 tesla. Magnetic Resonance in Medicine, 2017, 78, 2095-2105.	1.9	25
135	Protecting travellers from hepatitis A. BMJ: British Medical Journal, 2001, 322, 1194-1195.	2.4	24
136	Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection. MBio, 2019, 10, .	1.8	24
137	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7, .	2.3	24
138	The surveillance and diagnosis of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 491-496.	0.8	23
139	Effect of interferon-Î± on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychological Medicine, 2014, 44, 789-795.	2.7	23
140	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. Journal of Infection, 2019, 79, 503-512.	1.7	23
141	Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus. Wellcome Open Research, 2016, 1, 9.	0.9	23
142	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 32-44.	3.7	22
143	Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6. Journal of General Virology, 2013, 94, 76-80.	1.3	21
144	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. Vaccines, 2020, 8, 184.	2.1	21

#	Article	IF	Citations
145	T Cell Failure in Hepatitis C Virus Infection. Viral Immunology, 2002, 15, 285-293.	0.6	20
146	Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. Journal of Viral Hepatitis, 2004, 11, 324-331.	1.0	20
147	MHC class II invariant chainâ€“adjuvanted viral vectored vaccines enhances T cell responses in humans. Science Translational Medicine, 2020, 12, .	5.8	20
148	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	20
149	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	5.8	20
150	â€˜Favourableâ€™ IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. Journal of General Virology, 2013, 94, 1259-1265.	1.3	19
151	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infectious Diseases, 2018, 18, 461.	1.3	19
152	NK cells limit therapeutic vaccineâ€“induced CD8 ⁺ T cell immunity in a PD-L1â€“dependent manner. Science Translational Medicine, 2022, 14, eabi4670.	5.8	19
153	Acute Hepatitis C: Clinical Aspects, Diagnosis, and Outcome of Acute HCV Infection. Current Pharmaceutical Design, 2008, 14, 1661-1665.	0.9	18
154	New Approaches for Biomarker Discovery: The Search for Liver Fibrosis Markers in Hepatitis C Patients. Journal of Proteome Research, 2011, 10, 2643-2650.	1.8	18
155	Impact of Interferon Lambda 4 Genotype on Interferonâ€Stimulated Gene Expression During Directâ€Acting Antiviral Therapy for Hepatitis C. Hepatology, 2018, 68, 859-871.	3.6	18
156	Interferon-Î± induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study. Psychological Medicine, 2018, 48, 998-1007.	2.7	18
157	Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. Hepatology, 2020, 71, 794-807.	3.6	18
158	Divergent chemokine receptor expression and the consequence for human IgG4 BÂcell responses. European Journal of Immunology, 2020, 50, 1113-1125.	1.6	18
159	Analysis of â€˜driverâ€™ and â€˜passengerâ€™ CD8 + T-cell responses against variable viruses. Proceedings of the Royal Society B: Biological Sciences, 2004, 271, S53-6.	1.2	17
160	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Medicine, 2019, 17, 175.	2.3	17
161	Therapeutic vaccines in HBV: lessons from HCV. Medical Microbiology and Immunology, 2015, 204, 79-86.	2.6	16
162	IgG4â€related sclerosing cholangitis. Clinical Liver Disease, 2017, 10, 9-16.	1.0	16

#	Article	IF	Citations
163	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. Journal of Clinical Virology, 2020, 129, 104548.	1.6	16
164	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. Journal of Viral Hepatitis, 2021, 28, 1256-1264.	1.0	16
165	Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. Journal of Hepatology, 2021, 75, 226-228.	1.8	16
166	Infection of liver hepatocytes with SARS-CoV-2. Nature Metabolism, 2022, 4, 301-302.	5.1	16
167	Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. Journal of Hepatology, 1999, 31, 244-249.	1.8	15
168	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut, 2012, 61, 1589-1599.	6.1	15
169	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. Npj Vaccines, 2020, 5, 94.	2.9	15
170	Characterizing Hepatitis C Virusâ€“Specific CD4+ T Cells Following Viralâ€Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. Hepatology, 2020, 72, 1541-1555.	3.6	15
171	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	15
172	Hepatitis E Virus Infection, Papua New Guinea, Fiji, and Kiribati, 2003â€“2005. Emerging Infectious Diseases, 2014, 20, 1057-1058.	2.0	14
173	A 63-year-old man with a recurrent right-sided pleural effusion: FigureÂ1. Thorax, 2015, 70, 504-507.	2.7	14
174	Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Research, 2017, 146, 139-145.	1.9	14
175	National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research. BMJ Health and Care Informatics, 2020, 27, e100145.	1.4	14
176	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health, 2019, 22, 693-703.	0.1	13
177	Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Frontiers in Microbiology, 2020, 11, 576572.	1.5	13
178	Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine, 2020, 38, 5036-5048.	1.7	13
179	Accurate nonâ€invasive diagnosis and staging of nonâ€alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 2020, 51, 1188-1197.	1.9	13
180	T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet, The, 2005, 365, 327-329.	6.3	13

#	Article	IF	Citations
181	Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection. Antiviral Therapy, 2004, 9, 139-142.	0.6	13
182	Impaired humoral and cellular response to primary <scp>COVID</scp>â€19 vaccination in patients less than 2â€‰years after allogeneic bone marrow transplant. British Journal of Haematology, 2022, 198, 668-679.	1.2	13
183	PREDICTORS OF A FAVORABLE RESPONSE TO ALPHA INTERFERON THERAPY FOR HEPATITIS C. Clinics in Liver Disease, 1999, 3, 775-791.	1.0	12
184	Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. Hepatology, 2016, 64, 1377-1378.	3.6	12
185	Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations. Journal of Viral Hepatitis, 2021, 28, 1110-1120.	1.0	12
186	A panâ€genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. Hepatology, 2022, 76, 1190-1202.	3.6	12
187	Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. Abdominal Radiology, 2021, 46, 1947-1957.	1.0	11
188	The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization. Gastroenterology, 2021, 160, 2599-2601.e2.	0.6	11
189	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nature Communications, 2021, 12, 6105.	5.8	11
190	Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms. Wellcome Open Research, 2020, 5, 151.	0.9	10
191	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Reports, 2021, 3, 100384.	2.6	10
192	What Are the Prospects for Controlling Hepatitis C?. PLoS Medicine, 2009, 6, e1000096.	3.9	9
193	Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infectious Diseases, 2021, 21, 610.	1.3	9
194	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. Wellcome Open Research, 2020, 5, 113.	0.9	9
195	The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 2022, 6, 1213-1226.	2.0	9
196	Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease. Clinical and Translational Gastroenterology, 2020, 11, e00111.	1.3	8
197	Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS ONE, 2013, 8, e66749.	1.1	8
198	Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus. Rna, 2020, 26, 1541-1556.	1.6	7

#	Article	IF	Citations
199	Impact of directâ€acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2021, 28, 168-176.	1.0	7
200	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019. Hepatology Communications, 2021, 5, 1586-1604.	2.0	7
201	Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. Clinical Medicine, 2020, 20, e32-e39.	0.8	7
202	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 1741-1751.	1.4	6
203	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. Infection and Drug Resistance, 2018, Volume 11, 1119-1135.	1.1	6
204	Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. Journal of Interferon and Cytokine Research, 2019, 39, 642-649.	0.5	6
205	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. SSRN Electronic Journal, 0, , .	0.4	6
206	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infectious Diseases, 2021, 8, ofab267.	0.4	6
207	Immunology taught by rats. Science, 2017, 357, 129-130.	6.0	5
208	The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials, 2020, 21, 413.	0.7	5
209	SARSâ€CoVâ€2 in Pediatric Liver Transplant Recipients. Journal of Pediatric Gastroenterology and Nutrition, 2022, 74, .	0.9	5
210	Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. Wellcome Open Research, 2020, 5, 113.	0.9	5
211	Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead. Journal of Hepatology, 2022, 76, 981-982.	1.8	5
212	Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naÃ¯ve and convalescent healthcare workers. Clinical and Experimental Immunology, 2022, 209, 90-98.	1.1	5
213	Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. Hepatology, 2023, 77, 1757-1772.	3.6	5
214	The science, economics, and effectiveness of combination therapy for hepatitis C. Gut, 2000, 47, 159-161.	6.1	4
215	Emergence of a distinct <scp>HIV</scp>â€specific <scp>IL</scp>â€10â€producing <scp>CD</scp>8⁺<scp>T</scp>â€cell subset with immunomodulatory functions during chronic <scp>HIV</scp>â€1 infection. European Journal of Immunology, 2013, 43, 2875-2885.	1.6	4
216	Screening and treatment for hepatitis C: a balanced perspective. BMJ, The, 2015, 350, h644-h644.	3.0	4

#	Article	IF	Citations
217	Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. Journal of Clinical Investigation, 2018, 128, 573-576.	3.9	4
218	SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2022, , ASN.2021121587.	3.0	4
219	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells. Journal of Immunological Methods, 2022, 504, 113263.	0.6	4
220	The emerging mysteries of IgG4-related disease. Clinical Medicine, 2014, 14, s56-s60.	0.8	3
221	Hepatitis B vaccine shortage: another symptom of chronic neglect?. BMJ: British Medical Journal, 2017, 359, j4686.	2.4	3
222	Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. Journal of Hepatology, 2020, 73, S336.	1.8	3
223	Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination. Npj Vaccines, 2021, 6, 117.	2.9	3
224	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. Wellcome Open Research, 2020, 5, 240.	0.9	3
225	Adenovirus vectors activate VÎ2⁺ Î³ÎT cells in a type I interferonâ€, TNFâ€, and ILâ€18â€dependent manner. European Journal of Immunology, 2022, 52, 835-837.	1.6	3
226	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
227	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut, 2022, 71, 1919.2-1922.	6.1	3
228	Defining the key intrahepatic gene networks in HCV infection driven by sex. Gut, 2023, 72, 984-994.	6.1	3
229	A rare cause of an ileocaecal mass and lymphadenopathy. Gut, 2012, 61, 819-820.	6.1	2
230	Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis. Aids, 2015, 29, 982-985.	1.0	2
231	Reply to: â€œMultiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising techniqueâ€. Journal of Hepatology, 2017, 66, 457-458.	1.8	2
232	FRI-162-Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice. Journal of Hepatology, 2019, 70, e459-e460.	1.8	2
233	Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver. Journal of Hepatology, 2020, 73, S886.	1.8	2
234	Correspondence on â€˜The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Diseaseâ€™. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-218894.	0.5	2

#	Article	IF	Citations
235	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2
236	In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control. Wellcome Open Research, 0, 6, 47.	0.9	2
237	Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. Wellcome Open Research, 2020, 5, 240.	0.9	2
238	OTH-1â€...SARS-CoV-2 Infection in patients with autoimmune hepatitis. , 2021, , .		2
239	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis.. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	1.3	2
240	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. Efficacy and Mechanism Evaluation, 2022, 9, 1-54.	0.9	2
241	Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset. International Journal of Epidemiology, 0, , .	0.9	2
242	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-NaÃ¯ve Patients With Chronic Hepatitis C Virus. Value in Health, 2020, 23, 180-190.	0.1	1
243	COVID-19 and liver transplantation: the jury is still out â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 11.	3.7	1
244	O07â€...FXR antagonists as new agents for COVID19. , 2021, , .		1
245	P048â€...Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data. , 2021, , .		1
246	Vaccines in clinical trials: infectious disease. Expert Review of Vaccines, 2011, 10, 555-557.	2.0	0
247	OTU-020â€...Altered FC and FAB glycosylation status in patients with IGG4-related sclerosing cholangitis and autoimmune pancreatitis. , 2018, , .		0
248	IgG4-related disease. Medicine, 2019, 47, 804-807.	0.2	0
249	PTU-100â€...The role of a multi-regional specialist multi-disciplinary meeting in diagnosis and management of igg4-related disease. , 2019, , .		0
250	Genome-wide association study for alcohol-related cirrhosis identifies new risk loci in MARC1 and HNRNPUL1. Journal of Hepatology, 2020, 73, S117-S118.	1.8	0
251	A multi-disciplinary approach to igG4 related disease aids in diagnosis and management. Journal of Hepatology, 2020, 73, S487-S488.	1.8	0
252	The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis. Journal of Hepatology, 2020, 73, S773-S774.	1.8	0

#	Article	IF	Citations
253	Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. Virus Evolution, 2021, 7, veab065.	2.2	0
254	Induction and maintenance of CX3CR1-intermediate peripheral memory CD8 T cells by persistent viruses and novel vaccines. SSRN Electronic Journal, 0, , .	0.4	0
255	Immune Responses Against the Hepatitis C Virus and the Outcome of Therapy. , 2008, , 71-86.		0
256	Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Research, 0, 7, 51.	0.9	0